The Relational Sequencing TB Data Platform (ReSeqTB) catalogs a vast amount of genotypic, phenotypic and related metadata from Mycobacterium tuberculosis (Mtb) strains to enable the development of clinically useful, WHO-endorsed in vitro diagnostic assays for rapid drug susceptibility testing of Mtb. It provides a standardized and validated whole genome sequencing (WGS) analysis pipeline and a “one stop� source of curated, aggregated, clinically relevant genetic and associated metadata for global Mtb strains.

Having these standardized and validated data easily accessible under one platform will accelerate the development of rapid drug susceptibility tests for TB and will significantly improve diagnosis of drug resistant disease in TB patients.

This initiative is led by a collaborative partnership which includes the Bill & Melinda Gates Foundation (BMGF), Critical Path Institute (C-Path), Foundation for Innovative New Diagnostics (FIND), World Health Organization (WHO), US Centers for Disease Control and Prevention (CDC), New Diagnostics Working Group (NDWG), and the National Institute of Allergy and Infectious Diseases (NIAID).

To request access:
Submit an application